Wednesday, September 23, 2026

CF Industries Holdings, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

CF Industries Holdings, Inc. And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Proto Labs, Inc.

19.1% sales growth and 8.27% return on equity

Proto Labs, Inc., together with its subsidiaries, operates as an e-commerce driven digital manufacturer of custom prototypes and on-demand production parts in the worldwide.

Proto Labs, Inc.'s sales growth this year is expected to be 10.4% and 10.4% for next year.

Year-on-year quarterly revenue growth declined by 6%, now sitting on 434.4M for the twelve trailing months.

Proto Labs, Inc.'s sales growth for the next quarter is 19.1%. The company's growth estimates for the present quarter and the next is a negative 32.8% and negative -13.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.27%.

Volatility

Proto Labs, Inc.'s last day, last week, and last month's current volatility was 2.89%, 2.10%, and 2.36%, respectively.

Proto Labs, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.02% (day), 4.45% (last week), and 5.98% (last month), respectively.

Proto Labs, Inc.'s Stock Yearly Top and Bottom Value

Proto Labs, Inc.'s stock is valued at $109.49 at 20:22 EST, way below its 52-week high of $286.57 and way higher than its 52-week low of $74.42.

Proto Labs, Inc.'s Moving Average

Proto Labs, Inc.'s value is way under its 50-day moving average of $137.77 and way below its 200-day moving average of $151.70.

3. CF Industries Holdings, Inc.

20.8% sales growth and 7.69% return on equity

CF Industries Holdings, Inc. manufactures and distributes nitrogen fertilizers and other nitrogen products worldwide.

CF Industries Holdings, Inc.'s sales growth this year is anticipated to be 14.8% and a negative 1.3% for next year.

Year-on-year quarterly revenue growth grew by 5.1%, now sitting on 4.12B for the twelve trailing months.

CF Industries Holdings, Inc.'s sales growth for the next quarter is 20.8%. The company's growth estimates for the current quarter and the next is 74.2% and 34.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.69%.

Volatility

CF Industries Holdings, Inc.'s last day, last week, and last month's current volatility was 1.08%, 0.97%, and 1.77%, respectively.

CF Industries Holdings, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.58% (day), 2.61% (last week), and 3.63% (last month), respectively.

CF Industries Holdings, Inc.'s Stock Yearly Top and Bottom Value

CF Industries Holdings, Inc.'s stock is valued at $46.01 at 20:22 EST, way under its 52-week high of $51.24 and way above its 52-week low of $23.05.

CF Industries Holdings, Inc.'s Moving Average

CF Industries Holdings, Inc.'s value is under its 50-day moving average of $47.00 and way higher than its 200-day moving average of $38.93.

4. A-Mark Precious Metals, Inc.

9.3% sales growth and 65.14% return on equity

A-Mark Precious Metals, Inc., together with its subsidiaries, operates as a precious metals trading company.

A-Mark Precious Metals, Inc.'s sales growth this year is anticipated to be 24.8% and 3.2% for next year.

Year-on-year quarterly revenue growth grew by 43.9%, now sitting on 6.31B for the twelve trailing months.

A-Mark Precious Metals, Inc.'s sales growth for the next quarter is 9.3%. The company's growth estimates for the present quarter and the next is 36.6% and negative -57.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 65.14%.

Volatility

A-Mark Precious Metals, Inc.'s last day, last week, and last month's current volatility was 4.87%, 1.63%, and 2.94%, respectively.

A-Mark Precious Metals, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 7.62% (day), 4.04% (last week), and 5.60% (last month), respectively.

A-Mark Precious Metals, Inc.'s Stock Yearly Top and Bottom Value

A-Mark Precious Metals, Inc.'s stock is valued at $38.80 at 20:22 EST, under its 52-week high of $40.09 and way higher than its 52-week low of $12.52.

A-Mark Precious Metals, Inc.'s Moving Average

A-Mark Precious Metals, Inc.'s value is way higher than its 50-day moving average of $33.24 and way above its 200-day moving average of $31.51.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com